HOME >> MEDICINE >> NEWS
Muscular dystrophy mouse model yields potential growth factor treatment

An altered mouse model of Duchenne muscular dystrophy, developed to have high levels of insulin-like growth factor I (IGF-I), has shown increases in muscle mass of at least 40 percent and other changes that could herald a possible treatment for secondary symptoms of the disease in humans. The new mouse, developed with support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the Muscular Dystrophy Association, has also resulted in reduced amounts of muscle-replacing fibrous tissue and enhanced biological pathways associated with muscle regeneration.

Duchenne muscular dystrophy, a genetic muscle-wasting disease caused by mutations in the gene for the protein dystrophin, results in repeated cycles of muscle damage and insufficient muscle regeneration, leading to gradual replacement of muscle by fibrous tissue. Since IGF-I is known to help regenerate muscle and enhance biological pathways for making proteins, the University of Pennsylvania's H. Lee Sweeney, M.D., and his colleagues tested its effects by creating a new mouse model a cross between a strain with muscular dystrophy symptoms and another with high levels of IGF-I. The hybrid mouse showed not only increases in muscle mass and muscle force generation, but also reduced muscle cell death, a combination that could have significant treatment implications.

"This is indeed good news for the muscular dystrophy community," said Stephen I. Katz, M.D., Ph.D., director of NIAMS. "The mouse model has helped our efforts against this disease more than once, and it looks like the search for answers has moved to another level."

The new mouse model offers an additional potential benefit, says Dr. Sweeney. "The combination of better muscle regeneration and less muscle wasting could lead to a better muscle capacity over time.

Less muscle effort would be needed to produce a required force, s
'"/>

Contact: Ray Fleming
flemingr@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
22-May-2002


Page: 1 2

Related medicine news :

1. McCaw/Muscular Dystrophy Association fund supports UW recruitment of internationally noted gene therapy researcher
2. Mayo Clinic researchers identify new form of muscular dystrophy in adults
3. New guideline: Corticosteroids recommended for duchenne muscular dystrophy
4. New centers boost muscular dystrophy research
5. Muscle stem cells show promise against muscular dystrophy in mouse model
6. Enzyme halts muscle waste in mouse models of most-common childhood muscular dystrophy
7. University of Pittsburgh researcher provides first-ever definition of HIV-associated lipodystrophy
8. UT Southwestern to study lipodystrophy syndrome in HIV-infected patients
9. UI study identifies mechanism that causes cardiomyopathy, exacerbates muscular dystrophy
10. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
11. UCSD-Utah team develops mouse model to test therapies for macular degeneration

Post Your Comments:
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once ... to provide logistics and support for one of Dallas’ largest ... long history of giving back to the community in which ... Toy Drive were Whataburger® and 99.5 The Wolf. , There ... Providing gifts to children who would otherwise not receive any ...
(Date:12/22/2014)... NAPW honors Michelle ... the Year. Ms. Foley is recognized with this prestigious ... networking organization of professional women in the country, spanning ... Professional Women is a powerfully vibrant networking community with ... “As a nurse, I felt like I made a ...
(Date:12/22/2014)... BROOK, Ill. (PRWEB) December 21, 2014 ... radiologist recommendations for chest computed tomography (CT) to ... clinically relevant findings, including cancer, according to a ... , Researchers said the findings show that ... X-rays represent valuable contributions to patient care. , ...
(Date:12/22/2014)... DC (PRWEB) December 22, 2014 ... Leadership Conference, next month in San Antonio, ... to address dynamics that often stand in the ... and competition. , This premier faculty development ... for Transformational Leadership, whose mission is to assist ...
(Date:12/21/2014)... In this report, the global powered surgical instruments ... application. The market, by power source, is segmented ... the market covers the handpieces; power source and ... further subdivided into drills, saws, reamers, staplers, vessel ... drivers, and others. Moreover, the power source and ...
Breaking Medicine News(10 mins):Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
(Date:12/22/2014)... CHESTERBROOK, Pa. and STOCKHOLM ... AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today ... Use (CHMP) of the European Medicines Agency (EMA) has ... (collagenase clostridium histolyticum) for the treatment of adult men ... deformity of at least 30 degrees at the start ...
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
Cached News: